13F Holdings
中文EN

FLGT Fulgent Genetics, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1674930 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.7%
TTM net income YoY-111.5%
TTM EPS YoY-135.1%
Revenue 3-yr CAGR4.9%
Net income 3-yr CAGR—

Margins

Gross margin33.8%
Operating margin-39.2%
Net margin-27.5%
FCF margin-0.4%
EBITDA margin-32.8%

Returns

ROE-8.6%
ROA-7.9%
ROIC (approx.)-10.7%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets8.7%
Debt / equity0.00x
Current ratio5.34x
Interest coverage-1,307.88x

Cash quality & payout

Operating cash flow / net income-0.16x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue4.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$322.67M$283.47M$289.21M$618.97M$992.58M
Cost of revenue$191.80M$176.25M$184.76M$252.07M$215.53M
Gross profit$130.88M$107.22M$104.46M$366.90M$777.05M
R&D expense$53.91M$48.82M$41.44M$28.91M$24.22M
SG&A expense$116.66M$88.11M$89.00M$111.07M$50.73M
Operating income-$91.10M-$73.92M-$195.53M$178.53M$675.95M
Interest expense$75,000-$170,000$488,000$1.01M$117,000
Pretax income-$70.03M-$51.96M-$174.09M$184.03M$677.30M
Income tax-$8.39M-$8.14M$1.15M$42.10M$174.79M
Net income-$60.51M-$42.71M-$167.82M$143.40M$507.36M
EBITDA-$66.97M-$48.99M-$169.39M$211.19M$686.96M
EPS (diluted)—————
Weighted avg. shares (diluted)30.78M30.23M29.78M30.96M30.98M
Balance sheet
Cash & equivalents$50.19M$55.28M$97.47M$79.51M$164.89M
Short-term investments$285.88M$202.96M———
Receivables$84.76M$69.02M$51.13M$52.75M$138.91M
Current assets$550.49M$353.57M$507.85M$627.87M$611.96M
PP&E, net$112.55M$105.55M$83.46M$81.35M$62.29M
Goodwill$25.08M$22.05M$22.05M$143.03M$50.90M
Intangibles$133.28M$134.98M$143.05M$150.64M$35.91M
Total assets$1.21B$1.22B$1.24B$1.39B$1.28B
Current liabilities$84.97M$72.90M$73.02M$88.11M$105.31M
Total liabilities$106.81M$90.81M$102.04M$116.18M$112.84M
Shareholders' equity$1.11B$1.13B$1.14B$1.27B$1.16B
Shares outstanding31.08M30.84M29.65M29.44M30.16M
Cash flow statement
Operating cash flow-$101.64M$21.06M$27.00M$253.52M$538.58M
Capital expenditure$22.57M$40.31M$22.21M$18.77M$23.81M
Free cash flow-$124.21M-$19.25M$4.80M$234.75M$514.76M
Investing cash flow$111.37M-$58.35M$38.90M-$261.31M-$546.55M
Financing cash flow-$14.79M-$4.85M-$47.78M-$77.14M$85.41M
Depreciation & amortization$24.12M$24.93M$26.14M$32.66M$11.00M
Stock-based compensation$39.58M$44.48M$42.92M$32.64M$15.88M
Share buybacks$10.88M$225,000$25.06M$74.34M—

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.